Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397644 | 0.90 | TNIK (0.77) | TNIKTBK1 | |
| SCHEMBL3393595 | 0.86 | TNIK (0.72) | TNIK | |
| SCHEMBL16699019 | 0.86 | TNIK (1.00) | TNIK | |
| SCHEMBL3392237 | 0.84 | TNIK (0.76) | TNIK | |
| SCHEMBL3394878 | 0.83 | TNIK (0.75) | TNIK | |
| SCHEMBL3396750 | 0.83 | TNIK (0.57) | TNIK | |
| SCHEMBL3397542 | 0.83 | TNIK (0.73) | TNIKTBK1 | |
| SCHEMBL3392639 | 0.81 | TNIK (0.62) | TNIK | |
| SCHEMBL3397651 | 0.81 | TNIK (0.73) | TNIKTBK1 | |
| SCHEMBL3393673 | 0.80 | TNIK (0.67) | TNIKTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364149-B1 | TNIK INHIBITOR AND THE USE | NAT CANCER CT (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| WO-2010064111-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | TNIK 1/4885TBK1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.